Rhodococcus equi: A pathogen in immunocompetent patients

Dias, Meena; Bhat, P; Chandrakar, Sagar; Pinto, Hilda

doi:10.4103/2249-4863.120770

Cited by 10 publications

(8 citation statements)

References 4 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impact of this disease is not only limited to Latin America, but has lately been spreading toward North America as well as other parts of the globe . While the insect vector is still only present in Latin America and certain parts of North America, the disease can enter blood banks via (labor) migrants or infected travelers . Chagas disease occurs in two distinct phases.…”

Section: Introductionmentioning

confidence: 99%

Identification of Phenylpyrazolone Dimers as a New Class of Anti‐Trypanosoma cruzi Agents

et al. 2019

View full text Add to dashboard Cite

Chagas disease is becoming a worldwide problem; it is currently estimated that over six million people are infected. The two drugs in current use, benznidazole and nifurtimox, require long treatment regimens, show limited efficacy in the chronic phase of infection, and are known to cause adverse effects. Phenotypic screening of an in‐house library led to the identification of 2,2′‐methylenebis(5‐(4‐bromophenyl)‐4,4‐dimethyl‐2,4‐dihydro‐3H‐pyrazol‐3‐one), a phenyldihydropyrazolone dimer, which shows an in vitro pIC50 value of 5.4 against Trypanosoma cruzi. Initial optimization was done by varying substituents of the phenyl ring, after which attempts were made to replace the phenyl ring. Finally, the linker between the dimer units was varied, ultimately leading to 2,2′‐methylenebis(5‐(3‐bromo‐4‐methoxyphenyl)‐4,4‐dimethyl‐2,4‐dihydro‐3H‐pyrazol‐3‐one (NPD‐0228) as the most potent analogue. NPD‐0228 has an in vitro pIC50 value of 6.4 against intracellular amastigotes of T. cruzi and no apparent toxicity against the human MRC‐5 cell line and murine cardiac cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Identification of Phenylpyrazolone Dimers as a New Class of Anti‐Trypanosoma cruzi Agents

et al. 2019

View full text Add to dashboard Cite

show abstract

“…However, no environmental exposure that might have predisposed the patient to the R. equi infection was noted. Owing to the rarity of R. equi infection, a standard treatment regimen for this disease has not been established; however, a combination of antibiotics has been recommended [ 21 ]. The Sanford Guide to Antimicrobial Therapy recommends that the first line of anti-infective treatment of R. equi is azithromycin, levofloxacin, rifampicin, or a combination of the two.…”

Section: Discussionmentioning

confidence: 99%

Multiple systemic infections caused by Rhodococcus equi: a case report

Li,

Wu,

Cao

et al. 2024

Access Microbiology

View full text Add to dashboard Cite

Background. Rhodococcus equi is one of the most important causes of zoonotic infections from grazing animals. It poses a particular risk to immunocompromised individuals, including those who are undergoing long-term immunosuppressive therapy. Case presentation. We report a case of Rhodococcus equi infection in a 65-year-old man with a medical history of diabetes, hypertension, and Adult Still’s Disease, currently taking long-term hormone therapy. The non-human immunodeficiency virus (HIV)-infected patient had blood, lung tissue, and sputum samples infected with Rhodococcus equi . His condition initially failed to improve despite multiple therapies, including vancomycin and meropenem. Although his symptoms improved after shifting his antibiotics to cover for the causative agent, he did not completely recover upon hospital discharge. Conclusions. In recent years, the number of Rhodococcus equi cases has increased. This report describes a lethal case of Rhodococcus equi infection in a patient without HIV.

show abstract

“…Because bacteremia is quite common in Rhodococcus equi infections, the pathogen can be disseminated from the local infection site. Given the high incidence of pulmonary involvement, the infection may involve the mediastinal lymph nodes, but axillary lymphadenitis has also been described [5]. Previously, mediastinal lymphadenopathy was mostly found in immunocompromised patients [6].…”

Section: Commentmentioning

confidence: 99%

Isolated Mediastinal Lymphadenopathy Caused by Rhodococcus equi Infection

Tootsi

Tamm

Laisaar

2018

The Annals of Thoracic Surgery

View full text Add to dashboard Cite

Mediastinal lymphadenopathy is common finding in thoracic surgery, and it often requires morphologic confirmation to establish the definitive diagnosis. The most frequent diagnoses are metastatic lung cancer, sarcoidosis, lymphoma, tuberculosis, and other causes of granulomatous infections. Rhodococcus equi is a rare pathogen in humans that mostly affects immunocompromised patients. This report presents a case with isolated mediastinal lymphadenopathy caused by Rhodococcus equi infection in a 71-year-old immunocompetent patient.

show abstract

Rhodococcus equi: A pathogen in immunocompetent patients

Abstract: Rhodococcus equi is an uncommon human pathogen known to cause lung infections in immunocompromised patients. We report two cases of Rhodococcus infections in immunocompetent individuals, who were treated successfully.

Cited by 10 publications

References 4 publications

Identification of Phenylpyrazolone Dimers as a New Class of Anti‐Trypanosoma cruzi Agents

Identification of Phenylpyrazolone Dimers as a New Class of Anti‐Trypanosoma cruzi Agents

Multiple systemic infections caused by Rhodococcus equi: a case report

Isolated Mediastinal Lymphadenopathy Caused by Rhodococcus equi Infection

Contact Info

Product

Resources

About